Skip to main content

Advertisement

SpringerLink
Log in

Differentiating genomics companies

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Abstract

As the value of raw sequence data diminishes, genomics companies are evolving new competencies as providers of information, therapeutic products, or novel technology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

Author information

Authors and Affiliations

  1. an investment manager at Prelude Technology Investments, Sycamore Studios, New Road, Over, CB4 5PJ, Cambridge, UK

    Rob James

Authors
  1. Rob James
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

James, R. Differentiating genomics companies. Nat Biotechnol 18, 153–155 (2000). https://doi.org/10.1038/72597

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/72597

  • Springer Nature America, Inc.

Search

Navigation